Pyxis Oncology, Inc. (PYXS)

3,9700 +0,1700 (+4,47%) Alla chiusura: 04:00PM EDT

Pyxis Oncology, Inc.

321 Harrison Avenue
11th Floor, Suite 1
Boston, MA 02118
United States
617 221 9059
https://www.pyxisoncology.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 51

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Lara S. Sullivan M.D., MBA	CEO, President & Director	1,21M	N/D	N/D
Ms. Pamela Yanchik Connealy M.B.A.	CFO & COO	709,7k	N/D	1962
Dr. Ken Kobayashi FACP, M.D.	Chief Medical Officer	314,08k	N/D	1961
Mr. Jitendra Wadhane	Chief Accounting Officer, Senior VP of Finance & Corporate Controller	N/D	N/D	1981
Dr. Balu N. Balasubramanian Ph.D.	Interim Chief Technology Officer	N/D	N/D	N/D
Dr. Jan Pinkas Ph.D.	Chief Scientific Officer	N/D	N/D	N/D
Dr. Charles T. Gombar Ph.D.	Senior Vice President of Portfolio & Program Management	N/D	N/D	N/D
Mr. Stephen T. Worsley MBA	Senior VP & Chief Business Officer	N/D	N/D	1964

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Pyxis Oncology, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.